About Spur Therapeutics
Spur Therapeutics is a company based in Stevenage (United Kingdom) founded in 2015 was acquired by Syncona in November 2023. It operates as a B2B and Partnerships. Spur Therapeutics offers products and services including FLT201, Gene Therapy for Parkinson’s, and Gene Therapy for AMN. Spur Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Senti Biosciences, Neurocrine and PTC Therapeutics, among others.
- Headquarter Stevenage, United Kingdom
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Spur Therapeutics
Spur Therapeutics offers a comprehensive portfolio of products and services, including FLT201, Gene Therapy for Parkinson’s, and Gene Therapy for AMN.
Gene therapy candidate for treating Gaucher Disease.
Therapy aimed at modifying Parkinson’s Disease progression.
First-in-class treatment for adrenomyeloneuropathy.
Funding Insights of Spur Therapeutics
Detailed funding history for Spur Therapeutics
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Spur Therapeutics
Spur Therapeutics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Syncona.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare investments are managed via private equity by Syncona.
|
Locked | Locked | Locked |
Investor details for Spur Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Spur Therapeutics
Investment portfolio details for Spur Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Spur Therapeutics
Detailed financials for Spur Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Spur Therapeutics Comparisons
Peer comparison for Spur Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Spur Therapeutics
Spur Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Senti Biosciences, Neurocrine and PTC Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Cell-based therapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
Detailed competitors of Spur Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Spur Therapeutics
Complete news archive for Spur Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Spur Therapeutics
Spur Therapeutics was founded in 2015.
Spur Therapeutics is headquartered in Stevenage, United Kingdom. It is registered at Stevenage, Hertfordshire, United Kingdom.
Spur Therapeutics is a clinical-stage biotech firm focused on developing gene therapies that optimize components for effective treatment of chronic conditions. They target diseases such as Gaucher Disease, Parkinsons Disease, and AMN through clinical trials and innovative approaches. Based in the United Kingdom and United States, they emphasize partnerships and aim to halt disease progression with single-dose therapies. Their pipeline reflects a commitment to transforming genetic medicine for broader impact.
Spur Therapeutics's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Spur Therapeutics offers FLT201, Gene Therapy for Parkinson’s, and Gene Therapy for AMN.
Spur Therapeutics has 1 investor. Key investors include Syncona.